Events

AI and ML in Healthcare Virtual Event w/ Jackie Hunter

The opportunities and challenges of applying machine learning to drug discovery

Drug discovery and development is poised to be revitalised by artificial intelligence and machine learning. From improving target identification and validation, to better predicting the properties of molecules, new technologies offer the promise of getting more effective therapeutics to the patients who need them, faster. AI also thrives in fast-moving situations and has been successfully deployed during the coronavirus pandemic to discover existing medicines that can be repurposed to treat the virus.

Yet, moving the needle in this field is challenging, and requires the experts from two seemingly disparate fields, both of which focus on tackling exceptionally complex problems, to work together. Other barriers include access to data, particularly negative data and diverse datasets. In this talk, Professor Jackie Hunter will examine case studies of BenevolentAI’s own work and progress in the field, and discuss the opportunities and unique challenges of building an AI platform for drug discovery.

→ Register here


Jackie Hunter
Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.


More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020